Diadema Partners LP 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Diadema Partners LP disclosed 43 US equity positions worth $125.1m in its Q1 2025 13F filing. The largest position was REGN at 15.1% of the reported book, followed by LLY and JAZZ. Against the Q4 2024 filing, it opened 20 new positions, added to 17 and reduced 6 among the top 43 holdings.
What did Diadema Partners LP own in Q1 2025? Top 43 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | REGN REGENERON PHARMACEUTICALS | Healthcare | 15.1% | $18.9m | 29,828 | – | new |
| 2 | LLY ELI LILLY & CO | Healthcare | 12.7% | $15.9m | 19,302 | – | new |
| 3 | JAZZ JAZZ PHARMACEUTICALS PLC | Healthcare | 8.6% | $10.8m | 87,189 | 492% | added |
| 4 | TGTX TG THERAPEUTICS INC | Healthcare | 6.5% | $8.2m | 207,883 | 335% | added |
| 5 | ARGX ARGENX SE | Healthcare | 5.7% | $7.2m | 12,279 | 1708% | added |
| 6 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 5.5% | $6.9m | 62,247 | – | new |
| 7 | SLNOEUR SOLENO THERAPEUTICS INC | 5.3% | $6.6m | 93,002 | 29% | added | |
| 8 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 3.0% | $3.7m | 52,877 | – | new |
| 9 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 2.8% | $3.5m | 13,115 | – | new |
| 10 | PCVX VAXCYTE INC | Healthcare | 2.8% | $3.5m | 92,385 | 824% | added |
| 11 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 2.3% | $2.9m | 96,984 | – | new |
| 12 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 2.1% | $2.6m | 50,000 | -33% | reduced |
| 13 | SWTXUSD SPRINGWORKS THERAPEUTICS INC | 2.1% | $2.6m | 60,000 | – | new | |
| 14 | VKTX VIKING THERAPEUTICS INC | Healthcare | 2.0% | $2.5m | 104,121 | – | new |
| 15 | CNTA CENTESSA PHARMACEUTICALS PLC | 1.9% | $2.4m | 164,048 | 24% | added | |
| 16 | COGT COGENT BIOSCIENCES INC | Healthcare | 1.9% | $2.3m | 392,213 | 336% | added |
| 17 | VRDN VIRIDIAN THERAPEUTICS INC | Healthcare | 1.7% | $2.2m | 162,063 | 228% | added |
| 18 | SRRK SCHOLAR ROCK HLDG CORP | Healthcare | 1.5% | $1.9m | 57,923 | 9% | added |
| 19 | ETNBGBP 89BIO INC | 1.3% | $1.7m | 231,436 | – | new | |
| 20 | NVO NOVO-NORDISK A S | Healthcare | 1.3% | $1.7m | 24,618 | – | new |
| 21 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.2% | $1.6m | 135,509 | – | new | |
| 22 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.2% | $1.5m | 40,000 | -21% | reduced |
| 23 | SG7 SAGE THERAPEUTICS INC | 1.2% | $1.5m | 183,466 | – | new | |
| 24 | VTGN VISTAGEN THERAPEUTICS INC | 1.1% | $1.4m | 565,975 | 28% | added | |
| 25 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.0% | $1.3m | 8,321 | -67% | reduced |
| 26 | TRVI TREVI THERAPEUTICS INC | Healthcare | 0.9% | $1.1m | 180,000 | – | new |
| 27 | RLAY RELAY THERAPEUTICS INC | Healthcare | 0.9% | $1.1m | 426,346 | -16% | reduced |
| 28 | PCRX PACIRA BIOSCIENCES INC | Healthcare | 0.8% | $967.3k | 38,926 | – | new |
| 29 | URGN UROGEN PHARMA LTD | Healthcare | 0.7% | $843.0k | 76,220 | 52% | added |
| 30 | CLYM CLIMB BIO INC | 0.7% | $817.2k | 669,803 | 79% | added | |
| 31 | CYTK CYTOKINETICS INC | Healthcare | 0.6% | $803.8k | 20,000 | – | new |
| 32 | REPL REPLIMUNE GROUP INC | Healthcare | 0.6% | $726.7k | 74,530 | -35% | reduced |
| 33 | REVIVA PHARMACEUTCLS HLDGS I | 0.5% | $620.7k | 650,723 | – | new | |
| 34 | ALEC ALECTOR INC | Healthcare | 0.4% | $561.6k | 456,546 | 91% | added |
| 35 | QURE UNIQURE NV | 0.3% | $386.9k | 36,500 | – | new | |
| 36 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 0.3% | $376.0k | 100,000 | – | new |
| 37 | GOSS GOSSAMER BIO INC | Healthcare | 0.2% | $296.5k | 269,589 | 24% | added |
| 38 | PROQR THRAPEUTICS N V | 0.2% | $276.2k | 207,694 | 31% | added | |
| 39 | ELDN ELEDON PHARMACEUTICALS INC | 0.2% | $219.0k | 64,613 | -15% | reduced | |
| 40 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.1% | $168.5k | 492,215 | – | new |
| 41 | 430 TERNS PHARMACEUTICALS INC | 0.1% | $154.8k | 56,098 | 11% | added | |
| 42 | SGMT SAGIMET BIOSCIENCES INC | Healthcare | 0.1% | $150.0k | 46,019 | – | new |
| 43 | CADL CANDEL THERAPEUTICS INC | 0.1% | $141.5k | 25,045 | 25% | added |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.